Expected Moves

With just 35,000 in cash at the end of Q2 and a recent 60,000 equity placement, Glucose Health requires working capital to fund its 2,500-store national expansion. This liquidity need poses a risk to the $0.32 base price.

Glucose Health will report Q3 earnings, offering the first full-quarter financial look at GlucoDown sales since expanding to over 2,500 pharmacy locations. The market will look for revenue growth from the $0.20 base price.

The company previously teased a new soluble fiber brand to complement GlucoDown. A formal launch or commercial update is expected in Q1 2027 to drive momentum from the $0.30 base price.

Q4 earnings will establish whether the 2026 retail expansion yielded sustainable revenue growth and a path toward cash flow breakeven, testing the $0.38 base price.